Articles related to FDA

The FDA advisory committee’s decision highlights the complexities of perioperative treatment in NSCLC and the need for more precise efficacy data to guide clinical decision-making.

Roflumilast cream 0.15% demonstrates rapid and significant improvement in itch within 24 hours of the first application, addressing a primary concern for atopic dermatitis patients.

The recall of Snapchill coffee products due to potential botulinum toxin contamination highlights the importance of recognizing botulism symptoms and ensuring food safety compliance to prevent serious health risks.

The FDA has approved a combination therapy of pembrolizumab, carboplatin, and paclitaxel for advanced endometrial cancer, significantly enhancing progression-free survival rates for patients with both mismatch repair deficient and proficient statuses.

The FDA has withdrawn approval for infigratinib in advanced cholangiocarcinoma following Helsinn Healthcare SA’s request, citing recruitment difficulties for a confirmatory trial.

The FDA-approved Rejoyn app, designed for major depressive disorder, combines therapeutic exercises and emotional regulation training to complement antidepressant therapy, showing significant improvement in clinical trials.